Key leadership appointments at Mubadala Bio; Dr. Essam Mohamed named as CEO

The appointments, effective immediately, reflect the company’s commitment to operational excellence, strategic growth, and innovation. “While focusing on its dedication to advancing the life sciences industry, enhancing drug security, and ensuring access to high-quality essential medical therapies and devices, it also highlights Mubadala’s commitment to driving economic diversification in the UAE and fostering a knowledge-based economy powered by innovation and growth across key sectors,” the company said in its announcement. 

In his new role, Dr. Mohamed brings over 30 years of leadership experience to oversee Mubadala Bio’s operations and strategic direction. He has held senior leadership roles in both global and regional organizations, including MS Pharma, elkendi Pharmaceuticals, and Sanofi, and most recently as CEO of Julphar. “He has successfully led major turnarounds and transformations, advanced regulatory enhancements, and executed strategies that boosted both profitability and growth. Dr. Essam has spearheaded the establishment of multiple startups in the life sciences industry across the region, successfully scaling them into leading players within just a few years,” the company said. 

The new Deputy CEO, Al Marzooqi brings around 20 years of leadership experience. He is Mubadal’s home grown talent, as he held a series of senior leadership roles over the last few years across the UAE, Russia, Brazil and the UK. “Hamad’s career reflects extensive leadership across diverse sectors, marked by achievements in strategy development, deal sourcing and execution, portfolio management, and business turnaround. In his new role as Deputy CEO of Mubadala Bio, Hamad will build on his proven track record to drive strategy execution, foster partnerships, and accelerate business growth, advancing the company’s vision of becoming a global leader in the life sciences industry,” the statement added.

The new CFO, Azeem brings around three decades of finance, investments, treasury, accounting, and auditing experience. “He has held senior leadership roles overseeing large-scale finance operations across diverse sectors, including healthcare, aviation, oil and gas, power generation, real estate development, and technology. As CFO, Atif will lead Mubadala Bio’s financial strategy, ensuring strong governance, performance, and long-term value creation,” the company shared. 

Al-Kaf, the new General Manager of Pharma Logistics, brings around two decades of operations, IT, and digital transformation experience. “In his new role, he will lead the Pharma Logistics vertical, overseeing the procurement, logistics and distribution of essential and lifesaving medications and devices in a cost-efficient and timely manner,” the statement added. 

Welcoming the new leaders, Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform and Chairman of Mubadala Bio said, “We are proud to welcome leaders of this caliber to Mubadala Bio. Their experience, vision, and commitment to advancing the life sciences industry in the UAE will play a pivotal role in strengthening our capabilities, driving innovation, and supporting our mission to deliver better health, closer for all.” 

Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform added, “The life sciences sector is vital to building a resilient future for our nation and for the region. We are confident that Mubadala Bio’s executive leadership team will deliver transformative outcomes for the company as well as for the wider UAE life sciences ecosystem.”